private:ocusciences
|
3961979
|
May 30th, 2019 12:00AM
|
OcuSciences
|
37
|
5.00
|
Open
|
Medical Devices
|
May 30th, 2019 04:56PM
|
May 30th, 2019 04:56PM
|
OcuSciences is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique called flavoprotein fluorescence (FPF). FPF is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The first device, the OcuMet Beacon, is currently being developed and validated at several top ophthalmic centers.
|
Open
|
medical device, flavoprotein fluorescence, ophthalmology, AMD, glaucoma
|
Open
|
1777 Highland Drive
|
Ann Arbor
|
MI
|
US
|
48108
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 17th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 16th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 15th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 14th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 13th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 12th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 11th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 10th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|
private:ocusciences
|
3961979
|
Feb 9th, 2018 12:00AM
|
OcuSciences
|
34
|
5.00
|
Open
|
Medical Devices
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
OcuSciences, Inc., is a medical device company developing a rapid, unique and patented non-invasive ocular imaging technique. The technique, termed Retinal Metabolic Analysis (RMA), is being developed to detect retinal diseases, such as diabetic retinopathy, macular degeneration, and glaucoma, earlier than current clinical methods and before irreversible cell death becomes visible. The device, the OcuMet Beacon, assesses the level of flavoprotein fluorescence, which is correlated to mitochondrial health, in the retinal.
|
|
|
|
|
|
|
|
|
|
OcuSciences
|
|
|